| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| CRBU - Caribou Biosciences Inc | BUY | 1,332 @ USD 1.72 | USD 2,291 | The ETF bought 1332 new shares of CRBU (Caribou Biosciences Inc). The shares were bought for an average price of 1.72 compared to the previous average buy price of . This is 0.0% than average price of previous purchases of CRBU. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 3.72 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 3.72. The average price that ABCL shares were previous bought at was USD 3.82652. The current market price is -2.8% lower than average price they were purchased at. The value of the holding in ABCL has increased by USD 24,408 compared to the previous valuation of Abcellera Biologics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ABUS - Arbutus Biopharma Corp | HOLD | 0 @ USD 4.72 | USD 0 | The current share valuation price of ABUS based on adjusted close was USD 4.72. The average price that ABUS shares were previous bought at was USD 3.8558. The current market price is 22.4% higher than average price they were purchased at. The value of the holding in ABUS has increased by USD 38,155 compared to the previous valuation of Arbutus Biopharma Corp however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 28.06 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 28.06. The average price that ACAD shares were previous bought at was USD 22.1074. The current market price is 26.9% higher than average price they were purchased at. The value of the holding in ACAD has increased by USD 104,163 compared to the previous valuation of ACADIA Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ACIU - AC Immune Ltd | HOLD | 0 @ USD 3.18 | USD 0 | The current share valuation price of ACIU based on adjusted close was USD 3.18. The average price that ACIU shares were previous bought at was USD 2.58078. The current market price is 23.2% higher than average price they were purchased at. The value of the holding in ACIU has increased by USD 10,923 compared to the previous valuation of AC Immune Ltd however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 65.18 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 65.18. The average price that ACLX shares were previous bought at was USD 72.2348. The current market price is -9.8% lower than average price they were purchased at. The value of the holding in ACLX has increased by USD 48,258 compared to the previous valuation of Arcellx Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ACRS - Aclaris Therapeutics Inc | HOLD | 0 @ USD 3.07 | USD 0 | |
| ADMA - ADMA Biologics Inc | HOLD | 0 @ USD 19.88 | USD 0 | The current share valuation price of ADMA based on adjusted close was USD 19.88. The average price that ADMA shares were previous bought at was USD 17.8131. The current market price is 11.6% higher than average price they were purchased at. The value of the holding in ADMA has increased by USD 48,843 compared to the previous valuation of ADMA Biologics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 17.41 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 17.41. The average price that ADPT shares were previous bought at was USD 13.5056. The current market price is 28.9% higher than average price they were purchased at. The value of the holding in ADPT has increased by USD 42,820 compared to the previous valuation of Adaptive Biotechnologies Corp however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| AGIO - Agios Pharm | HOLD | 0 @ USD 24.95 | USD 0 | The current share valuation price of AGIO based on adjusted close was USD 24.95. The average price that AGIO shares were previous bought at was USD 33.837. The current market price is -26.3% lower than average price they were purchased at. The value of the holding in AGIO has increased by USD 19,547 compared to the previous valuation of Agios Pharm however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 28.63 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 28.63. The average price that ALKS shares were previous bought at was USD 30.0612. The current market price is -4.8% lower than average price they were purchased at. The value of the holding in ALKS has increased by USD 20,332 compared to the previous valuation of Alkermes Plc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ALLO - Allogene Therapeutics Inc | HOLD | 0 @ USD 1.47 | USD 0 | The current share valuation price of ALLO based on adjusted close was USD 1.47. The average price that ALLO shares were previous bought at was USD 1.34961. The current market price is 8.9% higher than average price they were purchased at. The value of the holding in ALLO has increased by USD 7,985 compared to the previous valuation of Allogene Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 407.73 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 407.73. The average price that ALNY shares were previous bought at was USD 387.87. The current market price is 5.1% higher than average price they were purchased at. The value of the holding in ALNY has increased by USD 677,843 compared to the previous valuation of Alnylam Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ALT - Altitude Group Plc | HOLD | 0 @ USD 4.14 | USD 0 | The current share valuation price of ALT based on adjusted close was USD 4.14. The average price that ALT shares were previous bought at was USD 4.91477. The current market price is -15.8% lower than average price they were purchased at. The value of the holding in ALT has increased by USD 17,131 compared to the previous valuation of Altitude Group Plc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| AMGN - Amgen Inc | HOLD | 0 @ USD 331.39 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 331.39. The average price that AMGN shares were previous bought at was USD 303.893. The current market price is 9.0% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 863,549 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 12.5 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 12.5. The average price that AMLX shares were previous bought at was USD 9.1744. The current market price is 36.2% higher than average price they were purchased at. The value of the holding in AMLX has increased by USD 36,061 compared to the previous valuation of Amylyx Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| AMPH - Amphastar P | HOLD | 0 @ USD 27.32 | USD 0 | The current share valuation price of AMPH based on adjusted close was USD 27.32. The average price that AMPH shares were previous bought at was USD 25.9418. The current market price is 5.3% higher than average price they were purchased at. The value of the holding in AMPH has increased by USD 22,634 compared to the previous valuation of Amphastar P however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | HOLD | 0 @ USD 12.82 | USD 0 | The current share valuation price of AMRX based on adjusted close was USD 12.82. The average price that AMRX shares were previous bought at was USD 9.67809. The current market price is 32.5% higher than average price they were purchased at. The value of the holding in AMRX has increased by USD 53,763 compared to the previous valuation of Amneal Pharmaceuticals, Inc. Class A Common Stock however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 50.33 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 50.33. The average price that ANAB shares were previous bought at was USD 28.5875. The current market price is 76.1% higher than average price they were purchased at. The value of the holding in ANAB has increased by USD 23,678 compared to the previous valuation of AnaptysBio Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ANIP - ANI Pharmaceuticals Inc | HOLD | 0 @ USD 80.72 | USD 0 | The current share valuation price of ANIP based on adjusted close was USD 80.72. The average price that ANIP shares were previous bought at was USD 75.802. The current market price is 6.5% higher than average price they were purchased at. The value of the holding in ANIP has fallen by USD 32,725 compared to the previous valuation of ANI Pharmaceuticals Inc |
| APGE - Apogee Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 78 | USD 0 | The current share valuation price of APGE based on adjusted close was USD 78. The average price that APGE shares were previous bought at was USD 56.7109. The current market price is 37.5% higher than average price they were purchased at. The value of the holding in APGE has fallen by USD 20,256 compared to the previous valuation of Apogee Therapeutics, Inc. Common Stock |
| APLS - Apellis Pharmaceuticals Inc | HOLD | 0 @ USD 25.4 | USD 0 | The current share valuation price of APLS based on adjusted close was USD 25.4. The average price that APLS shares were previous bought at was USD 21.1742. The current market price is 20.0% higher than average price they were purchased at. The value of the holding in APLS has increased by USD 64,916 compared to the previous valuation of Apellis Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 6.58998 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 6.58998. The average price that ARCT shares were previous bought at was USD 12.5039. The current market price is -47.3% lower than average price they were purchased at. The value of the holding in ARCT has increased by USD 1,246 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ARDX - Ardelyx Inc | HOLD | 0 @ USD 5.84 | USD 0 | The current share valuation price of ARDX based on adjusted close was USD 5.84. The average price that ARDX shares were previous bought at was USD 4.93508. The current market price is 18.3% higher than average price they were purchased at. The value of the holding in ARDX has increased by USD 26,595 compared to the previous valuation of Ardelyx Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ARGX - argenx NV ADR | HOLD | 0 @ USD 852.04 | USD 0 | The current share valuation price of ARGX based on adjusted close was USD 852.04. The average price that ARGX shares were previous bought at was USD 719.883. The current market price is 18.4% higher than average price they were purchased at. The value of the holding in ARGX has fallen by USD 58,749 compared to the previous valuation of argenx NV ADR |
| ARQT - Arcutis Biotherapeutics Inc | HOLD | 0 @ USD 29.9 | USD 0 | The current share valuation price of ARQT based on adjusted close was USD 29.9. The average price that ARQT shares were previous bought at was USD 20.3067. The current market price is 47.2% higher than average price they were purchased at. The value of the holding in ARQT has increased by USD 158,374 compared to the previous valuation of Arcutis Biotherapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 12.32 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 12.32. The average price that ARVN shares were previous bought at was USD 9.97558. The current market price is 23.5% higher than average price they were purchased at. The value of the holding in ARVN has increased by USD 28,120 compared to the previous valuation of Arvinas Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ARWR - Arrowhead Pharmaceuticals Inc | HOLD | 0 @ USD 69 | USD 0 | The current share valuation price of ARWR based on adjusted close was USD 69. The average price that ARWR shares were previous bought at was USD 30.5514. The current market price is 125.8% higher than average price they were purchased at. The value of the holding in ARWR has increased by USD 78,042 compared to the previous valuation of Arrowhead Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ASND - Ascendis Pharma AS | HOLD | 0 @ USD 209.43 | USD 0 | The current share valuation price of ASND based on adjusted close was USD 209.43. The average price that ASND shares were previous bought at was USD 186.741. The current market price is 12.1% higher than average price they were purchased at. The value of the holding in ASND has increased by USD 396,489 compared to the previous valuation of Ascendis Pharma AS however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 16.31 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 16.31. The average price that AUPH shares were previous bought at was USD 11.4185. The current market price is 42.8% higher than average price they were purchased at. The value of the holding in AUPH has increased by USD 11,725 compared to the previous valuation of Aurinia Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| AUTL - Autolus Therapeutics Ltd | HOLD | 0 @ USD 1.73 | USD 0 | The current share valuation price of AUTL based on adjusted close was USD 1.73. The average price that AUTL shares were previous bought at was USD 1.72671. The current market price is 0.2% higher than average price they were purchased at. The value of the holding in AUTL has increased by USD 12,950 compared to the previous valuation of Autolus Therapeutics Ltd however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| AVIR - Atea Pharmaceuticals Inc | HOLD | 0 @ USD 3.17 | USD 0 | The current share valuation price of AVIR based on adjusted close was USD 3.17. The average price that AVIR shares were previous bought at was USD 3.23853. The current market price is -2.1% lower than average price they were purchased at. The value of the holding in AVIR has increased by USD 1,833 compared to the previous valuation of Atea Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| AVXL - Anavex Life Sciences Corp | HOLD | 0 @ USD 3.75 | USD 0 | The current share valuation price of AVXL based on adjusted close was USD 3.75. The average price that AVXL shares were previous bought at was USD 8.00044. The current market price is -53.1% lower than average price they were purchased at. The value of the holding in AVXL has increased by USD 5,005 compared to the previous valuation of Anavex Life Sciences Corp however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 154.7 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 154.7. The average price that AXSM shares were previous bought at was USD 124.03. The current market price is 24.7% higher than average price they were purchased at. The value of the holding in AXSM has increased by USD 70,698 compared to the previous valuation of Axsome Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| AZN - AstraZeneca PLC | HOLD | 0 @ USD 91.55 | USD 0 | The current share valuation price of AZN based on adjusted close was USD 91.55. The average price that AZN shares were previous bought at was USD 79.8243. The current market price is 14.7% higher than average price they were purchased at. The value of the holding in AZN has increased by USD 75,871 compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| BBIO - BridgeBio Pharma Inc | HOLD | 0 @ USD 77.09 | USD 0 | The current share valuation price of BBIO based on adjusted close was USD 77.09. The average price that BBIO shares were previous bought at was USD 52.3545. The current market price is 47.2% higher than average price they were purchased at. The value of the holding in BBIO has increased by USD 104,147 compared to the previous valuation of BridgeBio Pharma Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.61 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.61. The average price that BCRX shares were previous bought at was USD 8.03325. The current market price is -5.3% lower than average price they were purchased at. The value of the holding in BCRX has increased by USD 28,807 compared to the previous valuation of BioCryst Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| BCYC - Bicycle Therapeutics Ltd | HOLD | 0 @ USD 7.19001 | USD 0 | The current share valuation price of BCYC based on adjusted close was USD 7.19001. The average price that BCYC shares were previous bought at was USD 8.15311. The current market price is -11.8% lower than average price they were purchased at. The value of the holding in BCYC has increased by USD 11,043 compared to the previous valuation of Bicycle Therapeutics Ltd however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 27.92 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 27.92. The average price that BEAM shares were previous bought at was USD 21.9747. The current market price is 27.1% higher than average price they were purchased at. The value of the holding in BEAM has increased by USD 93,715 compared to the previous valuation of Beam Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 174.7 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 174.7. The average price that BIIB shares were previous bought at was USD 149.792. The current market price is 16.6% higher than average price they were purchased at. The value of the holding in BIIB has fallen by USD 10,035 compared to the previous valuation of Biogen Inc |
| BMRN - Biomarin Pharmaceutical Inc | HOLD | 0 @ USD 59.28 | USD 0 | The current share valuation price of BMRN based on adjusted close was USD 59.28. The average price that BMRN shares were previous bought at was USD 57.025. The current market price is 4.0% higher than average price they were purchased at. The value of the holding in BMRN has fallen by USD 245,765 compared to the previous valuation of Biomarin Pharmaceutical Inc |
| BNTX - BioNTech SE | HOLD | 0 @ USD 92.17 | USD 0 | The current share valuation price of BNTX based on adjusted close was USD 92.17. The average price that BNTX shares were previous bought at was USD 102.872. The current market price is -10.4% lower than average price they were purchased at. The value of the holding in BNTX has fallen by USD 22,824 compared to the previous valuation of BioNTech SE |
| CABA - Cabaletta Bio Inc | HOLD | 0 @ USD 2.38999 | USD 0 | |
| CGEM - Cullinan Oncology LLC | HOLD | 0 @ USD 10.34 | USD 0 | The current share valuation price of CGEM based on adjusted close was USD 10.34. The average price that CGEM shares were previous bought at was USD 8.59538. The current market price is 20.3% higher than average price they were purchased at. The value of the holding in CGEM has increased by USD 26,213 compared to the previous valuation of Cullinan Oncology LLC however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 40.08 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 40.08. The average price that CGON shares were previous bought at was USD 33.194. The current market price is 20.7% higher than average price they were purchased at. The value of the holding in CGON has increased by USD 57,662 compared to the previous valuation of CG Oncology, Inc. Common stock however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| CNTA - Centessa Pharmaceuticals PLC ADR | HOLD | 0 @ USD 25.38 | USD 0 | The current share valuation price of CNTA based on adjusted close was USD 25.38. The average price that CNTA shares were previous bought at was USD 19.607. The current market price is 29.4% higher than average price they were purchased at. The value of the holding in CNTA has increased by USD 34,980 compared to the previous valuation of Centessa Pharmaceuticals PLC ADR however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| COGT - Cogent Biosciences Inc | HOLD | 0 @ USD 39.34 | USD 0 | The current share valuation price of COGT based on adjusted close was USD 39.34. The average price that COGT shares were previous bought at was USD 20.0773. The current market price is 95.9% higher than average price they were purchased at. The value of the holding in COGT has fallen by USD 22,053 compared to the previous valuation of Cogent Biosciences Inc |
| COLL - Collegium Pharmaceutical Inc | HOLD | 0 @ USD 48.84 | USD 0 | The current share valuation price of COLL based on adjusted close was USD 48.84. The average price that COLL shares were previous bought at was USD 35.7679. The current market price is 36.5% higher than average price they were purchased at. The value of the holding in COLL has fallen by USD 865 compared to the previous valuation of Collegium Pharmaceutical Inc |
| CRNX - Crinetics Pharmaceuticals Inc | HOLD | 0 @ USD 49.24 | USD 0 | The current share valuation price of CRNX based on adjusted close was USD 49.24. The average price that CRNX shares were previous bought at was USD 38.1494. The current market price is 29.1% higher than average price they were purchased at. The value of the holding in CRNX has increased by USD 79,846 compared to the previous valuation of Crinetics Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| CRSP - Crispr Therapeutics AG | HOLD | 0 @ USD 57.91 | USD 0 | The current share valuation price of CRSP based on adjusted close was USD 57.91. The average price that CRSP shares were previous bought at was USD 53.2024. The current market price is 8.8% higher than average price they were purchased at. The value of the holding in CRSP has increased by USD 133,649 compared to the previous valuation of Crispr Therapeutics AG however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 41.39 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 41.39. The average price that CSTL shares were previous bought at was USD 26.4684. The current market price is 56.4% higher than average price they were purchased at. The value of the holding in CSTL has increased by USD 38,912 compared to the previous valuation of Castle Biosciences Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 9.57 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 9.57. The average price that DAWN shares were previous bought at was USD 7.73772. The current market price is 23.7% higher than average price they were purchased at. The value of the holding in DAWN has increased by USD 22,654 compared to the previous valuation of Day One Biopharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| DNLI - Denali Therapeutics Inc | HOLD | 0 @ USD 17.47 | USD 0 | The current share valuation price of DNLI based on adjusted close was USD 17.47. The average price that DNLI shares were previous bought at was USD 16.2138. The current market price is 7.7% higher than average price they were purchased at. The value of the holding in DNLI has increased by USD 62,206 compared to the previous valuation of Denali Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 11.16 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 11.16. The average price that DVAX shares were previous bought at was USD 10.6292. The current market price is 5.0% higher than average price they were purchased at. The value of the holding in DVAX has increased by USD 24,099 compared to the previous valuation of Dynavax Technologies Corporation however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| DYN - Dyne Therapeutics Inc | HOLD | 0 @ USD 20.78 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 20.78. The average price that DYN shares were previous bought at was USD 14.9005. The current market price is 39.5% higher than average price they were purchased at. The value of the holding in DYN has increased by USD 90,867 compared to the previous valuation of Dyne Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | HOLD | 0 @ USD 20.78 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 20.78. The average price that DYN shares were previous bought at was USD 14.9005. The current market price is 39.5% higher than average price they were purchased at. The value of the holding in DYN has increased by USD 90,867 compared to the previous valuation of DYNAGREEN EN.PR.GR.H YC 1 however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| EDIT - Editas Medicine Inc | HOLD | 0 @ USD 2.33001 | USD 0 | The current share valuation price of EDIT based on adjusted close was USD 2.33001. The average price that EDIT shares were previous bought at was USD 2.61421. The current market price is -10.9% lower than average price they were purchased at. The value of the holding in EDIT has fallen by USD 699 compared to the previous valuation of Editas Medicine Inc |
| ELVN - Enliven Therapeutics Inc. | HOLD | 0 @ USD 17.93 | USD 0 | The current share valuation price of ELVN based on adjusted close was USD 17.93. The average price that ELVN shares were previous bought at was USD 20.9173. The current market price is -14.3% lower than average price they were purchased at. The value of the holding in ELVN has increased by USD 42,497 compared to the previous valuation of Enliven Therapeutics Inc. however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| EOLS - Evolus Inc | HOLD | 0 @ USD 7.19 | USD 0 | The current share valuation price of EOLS based on adjusted close was USD 7.19. The average price that EOLS shares were previous bought at was USD 8.55984. The current market price is -16.0% lower than average price they were purchased at. The value of the holding in EOLS has increased by USD 5,321 compared to the previous valuation of Evolus Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| EWTX - Edgewise Therapeutics Inc | HOLD | 0 @ USD 20.94 | USD 0 | The current share valuation price of EWTX based on adjusted close was USD 20.94. The average price that EWTX shares were previous bought at was USD 18.0442. The current market price is 16.0% higher than average price they were purchased at. The value of the holding in EWTX has fallen by USD 333,874 compared to the previous valuation of Edgewise Therapeutics Inc |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 46.19 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 46.19. The average price that EXEL shares were previous bought at was USD 41.7182. The current market price is 10.7% higher than average price they were purchased at. The value of the holding in EXEL has increased by USD 346,653 compared to the previous valuation of Exelixis Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| FDMT - 4D Molecular Therapeutics Inc | HOLD | 0 @ USD 8.70999 | USD 0 | The current share valuation price of FDMT based on adjusted close was USD 8.70999. The average price that FDMT shares were previous bought at was USD 7.85517. The current market price is 10.9% higher than average price they were purchased at. The value of the holding in FDMT has increased by USD 1,091 compared to the previous valuation of 4D Molecular Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| FOLD - Amicus Therapeutics Inc | HOLD | 0 @ USD 14.21 | USD 0 | The current share valuation price of FOLD based on adjusted close was USD 14.21. The average price that FOLD shares were previous bought at was USD 8.13244. The current market price is 74.7% higher than average price they were purchased at. The value of the holding in FOLD has increased by USD 6,332 compared to the previous valuation of Amicus Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 17.69 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 17.69. The average price that FTRE shares were previous bought at was USD 8.51315. The current market price is 107.8% higher than average price they were purchased at. The value of the holding in FTRE has fallen by USD 3,155 compared to the previous valuation of Fortrea Holdings Inc. |
| FULC - Fulcrum Therapeutics Inc | HOLD | 0 @ USD 12.78 | USD 0 | |
| GERN - Geron Corporation | HOLD | 0 @ USD 1.35 | USD 0 | The current share valuation price of GERN based on adjusted close was USD 1.35. The average price that GERN shares were previous bought at was USD 1.44548. The current market price is -6.6% lower than average price they were purchased at. The value of the holding in GERN has increased by USD 8,532 compared to the previous valuation of Geron Corporation however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| GH - Guardant Health Inc | HOLD | 0 @ USD 101.34 | USD 0 | The current share valuation price of GH based on adjusted close was USD 101.34. The average price that GH shares were previous bought at was USD 69.0772. The current market price is 46.7% higher than average price they were purchased at. The value of the holding in GH has increased by USD 141,608 compared to the previous valuation of Guardant Health Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 124.16 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 124.16. The average price that GILD shares were previous bought at was USD 117.641. The current market price is 5.5% higher than average price they were purchased at. The value of the holding in GILD has fallen by USD 76,854 compared to the previous valuation of Guild Esports Plc |
| GLPG - Galapagos NV ADR | HOLD | 0 @ USD 32.48 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 32.48. The average price that GLPG shares were previous bought at was USD 29.6758. The current market price is 9.4% higher than average price they were purchased at. The value of the holding in GLPG has increased by USD 1,146 compared to the previous valuation of Galapagos NV ADR however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| GLPG - Galapagos N.V. | HOLD | 0 @ USD 32.48 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 32.48. The average price that GLPG shares were previous bought at was USD 29.6758. The current market price is 9.4% higher than average price they were purchased at. The value of the holding in GLPG has increased by USD 1,146 compared to the previous valuation of Galapagos N.V. however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| GMAB - Genmab AS | HOLD | 0 @ USD 33.06 | USD 0 | The current share valuation price of GMAB based on adjusted close was USD 33.06. The average price that GMAB shares were previous bought at was USD 28.2532. The current market price is 17.0% higher than average price they were purchased at. The value of the holding in GMAB has increased by USD 27,191 compared to the previous valuation of Genmab AS however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | HOLD | 0 @ USD 63.25 | USD 0 | The current share valuation price of GPCR based on adjusted close was USD 63.25. The average price that GPCR shares were previous bought at was USD 31.0398. The current market price is 103.8% higher than average price they were purchased at. The value of the holding in GPCR has fallen by USD 77,251 compared to the previous valuation of Structure Therapeutics Inc. American Depositary Shares |
| GRAL - GRAIL, LLC | HOLD | 0 @ USD 94.35 | USD 0 | The current share valuation price of GRAL based on adjusted close was USD 94.35. The average price that GRAL shares were previous bought at was USD 64.6396. The current market price is 46.0% higher than average price they were purchased at. The value of the holding in GRAL has increased by USD 86,559 compared to the previous valuation of GRAIL, LLC however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| GRFS - Grifols SA ADR | HOLD | 0 @ USD 9.07999 | USD 0 | The current share valuation price of GRFS based on adjusted close was USD 9.07999. The average price that GRFS shares were previous bought at was USD 9.17332. The current market price is -1.0% lower than average price they were purchased at. The value of the holding in GRFS has increased by USD 5,007 compared to the previous valuation of Grifols SA ADR however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 68.16 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 68.16. The average price that HALO shares were previous bought at was USD 61.6901. The current market price is 10.5% higher than average price they were purchased at. The value of the holding in HALO has increased by USD 65,163 compared to the previous valuation of Halozyme Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 38.86 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 38.86. The average price that HRMY shares were previous bought at was USD 33.4092. The current market price is 16.3% higher than average price they were purchased at. The value of the holding in HRMY has increased by USD 41,371 compared to the previous valuation of Harmony Biosciences Holdings however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| HROW - Harrow Health Inc | HOLD | 0 @ USD 49.38 | USD 0 | The current share valuation price of HROW based on adjusted close was USD 49.38. The average price that HROW shares were previous bought at was USD 37.2233. The current market price is 32.7% higher than average price they were purchased at. The value of the holding in HROW has increased by USD 75,504 compared to the previous valuation of Harrow Health Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| HUMA - Humacyte Inc | HOLD | 0 @ USD 1.07 | USD 0 | The current share valuation price of HUMA based on adjusted close was USD 1.07. The average price that HUMA shares were previous bought at was USD 1.98092. The current market price is -46.0% lower than average price they were purchased at. The value of the holding in HUMA has fallen by USD 4,745 compared to the previous valuation of Humacyte Inc |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.27 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.27. The average price that IBRX shares were previous bought at was USD 2.63096. The current market price is -13.7% lower than average price they were purchased at. The value of the holding in IBRX has increased by USD 127,954 compared to the previous valuation of Immunitybio Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 35.5 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 35.5. The average price that IDYA shares were previous bought at was USD 26.2915. The current market price is 35.0% higher than average price they were purchased at. The value of the holding in IDYA has increased by USD 116,945 compared to the previous valuation of Ideaya Biosciences Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 137.6 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 137.6. The average price that ILMN shares were previous bought at was USD 105.853. The current market price is 30.0% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 294,775 compared to the previous valuation of Illumina Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| IMCR - Immunocore Holdings Ltd | HOLD | 0 @ USD 35.98 | USD 0 | The current share valuation price of IMCR based on adjusted close was USD 35.98. The average price that IMCR shares were previous bought at was USD 34.3307. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in IMCR has fallen by USD 894 compared to the previous valuation of Immunocore Holdings Ltd |
| IMVT - Immunovant Inc | HOLD | 0 @ USD 27.54 | USD 0 | The current share valuation price of IMVT based on adjusted close was USD 27.54. The average price that IMVT shares were previous bought at was USD 19.2313. The current market price is 43.2% higher than average price they were purchased at. The value of the holding in IMVT has increased by USD 103,119 compared to the previous valuation of Immunovant Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| INCY - Incyte Corporation | HOLD | 0 @ USD 100.71 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 100.71. The average price that INCY shares were previous bought at was USD 81.7215. The current market price is 23.2% higher than average price they were purchased at. The value of the holding in INCY has fallen by USD 265,922 compared to the previous valuation of Incyte Corporation |
| INSM - Insmed Inc | HOLD | 0 @ USD 175.76 | USD 0 | The current share valuation price of INSM based on adjusted close was USD 175.76. The average price that INSM shares were previous bought at was USD 142.756. The current market price is 23.1% higher than average price they were purchased at. The value of the holding in INSM has increased by USD 134,228 compared to the previous valuation of Insmed Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| INVA - Innoviva Inc | HOLD | 0 @ USD 19.99 | USD 0 | The current share valuation price of INVA based on adjusted close was USD 19.99. The average price that INVA shares were previous bought at was USD 19.6892. The current market price is 1.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Innoviva Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| IONS - Ionis Pharmaceuticals Inc | HOLD | 0 @ USD 81.34 | USD 0 | The current share valuation price of IONS based on adjusted close was USD 81.34. The average price that IONS shares were previous bought at was USD 57.1725. The current market price is 42.3% higher than average price they were purchased at. The value of the holding in IONS has increased by USD 196,127 compared to the previous valuation of Ionis Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.78 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.78. The average price that IOVA shares were previous bought at was USD 2.39299. The current market price is 16.2% higher than average price they were purchased at. The value of the holding in IOVA has increased by USD 77,284 compared to the previous valuation of Iovance Biotherapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| IRON - Ironveld Plc | HOLD | 0 @ USD 79.54 | USD 0 | The current share valuation price of IRON based on adjusted close was USD 79.54. The average price that IRON shares were previous bought at was USD 66.3852. The current market price is 19.8% higher than average price they were purchased at. The value of the holding in IRON has fallen by USD 12,806 compared to the previous valuation of Ironveld Plc |
| IRWD - Ironwood Pharmaceuticals Inc | HOLD | 0 @ USD 3.23 | USD 0 | The current share valuation price of IRWD based on adjusted close was USD 3.23. The average price that IRWD shares were previous bought at was USD 2.38219. The current market price is 35.6% higher than average price they were purchased at. The value of the holding in IRWD has increased by USD 11,129 compared to the previous valuation of Ironwood Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 14.09 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 14.09. The average price that JANX shares were previous bought at was USD 26.2738. The current market price is -46.4% lower than average price they were purchased at. The value of the holding in JANX has increased by USD 12,103 compared to the previous valuation of Janux Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| JAZZ - Jazz Pharmaceuticals PLC | HOLD | 0 @ USD 169.67 | USD 0 | The current share valuation price of JAZZ based on adjusted close was USD 169.67. The average price that JAZZ shares were previous bought at was USD 135.895. The current market price is 24.9% higher than average price they were purchased at. The value of the holding in JAZZ has increased by USD 111,405 compared to the previous valuation of Jazz Pharmaceuticals PLC however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| KALV - Kalvista Pharmaceuticals Inc | HOLD | 0 @ USD 15.84 | USD 0 | The current share valuation price of KALV based on adjusted close was USD 15.84. The average price that KALV shares were previous bought at was USD 13.5388. The current market price is 17.0% higher than average price they were purchased at. The value of the holding in KALV has increased by USD 21,093 compared to the previous valuation of Kalvista Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 43.52 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 43.52. The average price that KNSA shares were previous bought at was USD 32.9161. The current market price is 32.2% higher than average price they were purchased at. The value of the holding in KNSA has increased by USD 10,185 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| KROS - Keros Therapeutics Inc | HOLD | 0 @ USD 21.34 | USD 0 | The current share valuation price of KROS based on adjusted close was USD 21.34. The average price that KROS shares were previous bought at was USD 15.8802. The current market price is 34.4% higher than average price they were purchased at. The value of the holding in KROS has increased by USD 22,509 compared to the previous valuation of Keros Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| KRYS - Krystal Biotech Inc | HOLD | 0 @ USD 249.61 | USD 0 | The current share valuation price of KRYS based on adjusted close was USD 249.61. The average price that KRYS shares were previous bought at was USD 178.182. The current market price is 40.1% higher than average price they were purchased at. The value of the holding in KRYS has increased by USD 174,764 compared to the previous valuation of Krystal Biotech Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 11.27 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 11.27. The average price that KURA shares were previous bought at was USD 8.32957. The current market price is 35.3% higher than average price they were purchased at. The value of the holding in KURA has increased by USD 85,125 compared to the previous valuation of Kura Oncology Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| KYMR - Kymera Therapeutics Inc | HOLD | 0 @ USD 84.35 | USD 0 | The current share valuation price of KYMR based on adjusted close was USD 84.35. The average price that KYMR shares were previous bought at was USD 52.7782. The current market price is 59.8% higher than average price they were purchased at. The value of the holding in KYMR has increased by USD 17,719 compared to the previous valuation of Kymera Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| LEGN - Legend Biotech Corp | HOLD | 0 @ USD 22.69 | USD 0 | The current share valuation price of LEGN based on adjusted close was USD 22.69. The average price that LEGN shares were previous bought at was USD 32.55. The current market price is -30.3% lower than average price they were purchased at. The value of the holding in LEGN has increased by USD 44,353 compared to the previous valuation of Legend Biotech Corp however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 197.96 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 197.96. The average price that LGND shares were previous bought at was USD 149.754. The current market price is 32.2% higher than average price they were purchased at. The value of the holding in LGND has fallen by USD 31,910 compared to the previous valuation of Ligand Pharmaceuticals Incorporated |
| LYEL - Lyell Immunopharma Inc | HOLD | 0 @ USD 37.37 | USD 0 | The current share valuation price of LYEL based on adjusted close was USD 37.37. The average price that LYEL shares were previous bought at was USD 7.12732. The current market price is 424.3% higher than average price they were purchased at. The value of the holding in LYEL has increased by USD 56,386 compared to the previous valuation of Lyell Immunopharma Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| MDGL - Madrigal Pharmaceuticals Inc | HOLD | 0 @ USD 602.83 | USD 0 | The current share valuation price of MDGL based on adjusted close was USD 602.83. The average price that MDGL shares were previous bought at was USD 414.017. The current market price is 45.6% higher than average price they were purchased at. The value of the holding in MDGL has increased by USD 183,492 compared to the previous valuation of Madrigal Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 571.53 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 571.53. The average price that MEDP shares were previous bought at was USD 446.146. The current market price is 28.1% higher than average price they were purchased at. The value of the holding in MEDP has increased by USD 61,086 compared to the previous valuation of Medpace Holdings Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| MGTX - MeiraGTx Holdings PLC | HOLD | 0 @ USD 8.30001 | USD 0 | The current share valuation price of MGTX based on adjusted close was USD 8.30001. The average price that MGTX shares were previous bought at was USD 7.41976. The current market price is 11.9% higher than average price they were purchased at. The value of the holding in MGTX has increased by USD 14,291 compared to the previous valuation of MeiraGTx Holdings PLC however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| MIRM - Mirum Pharmaceuticals Inc | HOLD | 0 @ USD 81.07 | USD 0 | The current share valuation price of MIRM based on adjusted close was USD 81.07. The average price that MIRM shares were previous bought at was USD 59.567. The current market price is 36.1% higher than average price they were purchased at. The value of the holding in MIRM has increased by USD 117,076 compared to the previous valuation of Mirum Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 37.56 | USD 0 | The current share valuation price of MLYS based on adjusted close was USD 37.56. The average price that MLYS shares were previous bought at was USD 26.3812. The current market price is 42.4% higher than average price they were purchased at. The value of the holding in MLYS has increased by USD 39,522 compared to the previous valuation of Mineralys Therapeutics, Inc. Common Stock however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| MNKD - MannKind Corp | HOLD | 0 @ USD 5.99 | USD 0 | The current share valuation price of MNKD based on adjusted close was USD 5.99. The average price that MNKD shares were previous bought at was USD 4.97976. The current market price is 20.3% higher than average price they were purchased at. The value of the holding in MNKD has increased by USD 31,510 compared to the previous valuation of MannKind Corp however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| MNMD - Mind Medicine Inc | HOLD | 0 @ USD 13.3 | USD 0 | The current share valuation price of MNMD based on adjusted close was USD 13.3. The average price that MNMD shares were previous bought at was USD 10.4744. The current market price is 27.0% higher than average price they were purchased at. The value of the holding in MNMD has increased by USD 40,434 compared to the previous valuation of Mind Medicine Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| MRNA - Moderna Inc | HOLD | 0 @ USD 34.9 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 34.9. The average price that MRNA shares were previous bought at was USD 28.0088. The current market price is 24.6% higher than average price they were purchased at. The value of the holding in MRNA has increased by USD 293,988 compared to the previous valuation of Moderna Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.50001 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.50001. The average price that MRVI shares were previous bought at was USD 2.9452. The current market price is 18.8% higher than average price they were purchased at. The value of the holding in MRVI has increased by USD 6,945 compared to the previous valuation of Maravai Lifesciences Holdings Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 147.53 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 147.53. The average price that NBIX shares were previous bought at was USD 135.768. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in NBIX has increased by USD 172,566 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| NRIX - Nurix Therapeutics Inc | HOLD | 0 @ USD 19.34 | USD 0 | The current share valuation price of NRIX based on adjusted close was USD 19.34. The average price that NRIX shares were previous bought at was USD 14.6691. The current market price is 31.8% higher than average price they were purchased at. The value of the holding in NRIX has increased by USD 56,864 compared to the previous valuation of Nurix Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| NTLA - Intellia Therapeutics Inc | HOLD | 0 @ USD 9.70001 | USD 0 | The current share valuation price of NTLA based on adjusted close was USD 9.70001. The average price that NTLA shares were previous bought at was USD 11.4501. The current market price is -15.3% lower than average price they were purchased at. The value of the holding in NTLA has increased by USD 37,064 compared to the previous valuation of Intellia Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| NUVL - Nuvalent Inc | HOLD | 0 @ USD 105.72 | USD 0 | The current share valuation price of NUVL based on adjusted close was USD 105.72. The average price that NUVL shares were previous bought at was USD 88.9595. The current market price is 18.8% higher than average price they were purchased at. The value of the holding in NUVL has increased by USD 94,506 compared to the previous valuation of Nuvalent Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| NVAX - Novavax Inc | HOLD | 0 @ USD 6.89 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.89. The average price that NVAX shares were previous bought at was USD 7.2182. The current market price is -4.5% lower than average price they were purchased at. The value of the holding in NVAX has increased by USD 25,515 compared to the previous valuation of Novavax Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 6.89 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.89. The average price that NVAX shares were previous bought at was USD 7.2182. The current market price is -4.5% lower than average price they were purchased at. The value of the holding in NVAX has increased by USD 25,515 compared to the previous valuation of Hana Microelectronics Public Company Limited however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 13.44 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 13.44. The average price that NVCR shares were previous bought at was USD 15.442. The current market price is -13.0% lower than average price they were purchased at. The value of the holding in NVCR has increased by USD 45,964 compared to the previous valuation of Novocure Ltd however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| OABI - OmniAb Inc. | HOLD | 0 @ USD 2.05 | USD 0 | The current share valuation price of OABI based on adjusted close was USD 2.05. The average price that OABI shares were previous bought at was USD 1.88466. The current market price is 8.8% higher than average price they were purchased at. The value of the holding in OABI has fallen by USD 3,599 compared to the previous valuation of OmniAb Inc. |
| OCUL - Ocular Therapeutix Inc | HOLD | 0 @ USD 12.96 | USD 0 | The current share valuation price of OCUL based on adjusted close was USD 12.96. The average price that OCUL shares were previous bought at was USD 11.005. The current market price is 17.8% higher than average price they were purchased at. The value of the holding in OCUL has increased by USD 58,298 compared to the previous valuation of Ocular Therapeutix Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| OLMA - Olema Pharmaceuticals Inc | HOLD | 0 @ USD 28.18 | USD 0 | The current share valuation price of OLMA based on adjusted close was USD 28.18. The average price that OLMA shares were previous bought at was USD 12.7927. The current market price is 120.3% higher than average price they were purchased at. The value of the holding in OLMA has increased by USD 13,453 compared to the previous valuation of Olema Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ORIC - Oric Pharmaceuticals Inc | HOLD | 0 @ USD 8.4 | USD 0 | The current share valuation price of ORIC based on adjusted close was USD 8.4. The average price that ORIC shares were previous bought at was USD 10.7122. The current market price is -21.6% lower than average price they were purchased at. The value of the holding in ORIC has increased by USD 23,372 compared to the previous valuation of Oric Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 1.82 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 1.82. The average price that PACB shares were previous bought at was USD 1.72925. The current market price is 5.2% higher than average price they were purchased at. The value of the holding in PACB has fallen by USD 4,131 compared to the previous valuation of Pacific Biosciences of California |
| PAHC - Phibro Animal Health Corporation | HOLD | 0 @ USD 37.83 | USD 0 | The current share valuation price of PAHC based on adjusted close was USD 37.83. The average price that PAHC shares were previous bought at was USD 31.5346. The current market price is 20.0% higher than average price they were purchased at. The value of the holding in PAHC has increased by USD 8,453 compared to the previous valuation of Phibro Animal Health Corporation however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| PCRX - Pacira BioSciences, Inc. | HOLD | 0 @ USD 26.02 | USD 0 | The current share valuation price of PCRX based on adjusted close was USD 26.02. The average price that PCRX shares were previous bought at was USD 23.9147. The current market price is 8.8% higher than average price they were purchased at. The value of the holding in PCRX has fallen by USD 9,712 compared to the previous valuation of Pacira BioSciences, Inc. |
| PCVX - Vaxcyte Inc | HOLD | 0 @ USD 48.07 | USD 0 | The current share valuation price of PCVX based on adjusted close was USD 48.07. The average price that PCVX shares were previous bought at was USD 45.2658. The current market price is 6.2% higher than average price they were purchased at. The value of the holding in PCVX has increased by USD 147,761 compared to the previous valuation of Vaxcyte Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| PGEN - Precigen Inc | HOLD | 0 @ USD 4.38 | USD 0 | The current share valuation price of PGEN based on adjusted close was USD 4.38. The average price that PGEN shares were previous bought at was USD 2.99077. The current market price is 46.5% higher than average price they were purchased at. The value of the holding in PGEN has increased by USD 14,523 compared to the previous valuation of Precigen Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| PHAT - Phathom Pharmaceuticals Inc | HOLD | 0 @ USD 17.87 | USD 0 | The current share valuation price of PHAT based on adjusted close was USD 17.87. The average price that PHAT shares were previous bought at was USD 10.5986. The current market price is 68.6% higher than average price they were purchased at. The value of the holding in PHAT has increased by USD 16,546 compared to the previous valuation of Phathom Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| PHVS - Pharvaris BV | HOLD | 0 @ USD 27.07 | USD 0 | |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 280.4 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 280.4. The average price that PRAX shares were previous bought at was USD 125.803. The current market price is 122.9% higher than average price they were purchased at. The value of the holding in PRAX has increased by USD 127,961 compared to the previous valuation of Praxis Precision Medicines Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| PRME - Prime Medicine, Inc. Common Stock | HOLD | 0 @ USD 3.7 | USD 0 | The current share valuation price of PRME based on adjusted close was USD 3.7. The average price that PRME shares were previous bought at was USD 3.872. The current market price is -4.4% lower than average price they were purchased at. The value of the holding in PRME has increased by USD 7,620 compared to the previous valuation of Prime Medicine, Inc. Common Stock however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| PRTA - Prothena Corporation plc | HOLD | 0 @ USD 9.68001 | USD 0 | The current share valuation price of PRTA based on adjusted close was USD 9.68001. The average price that PRTA shares were previous bought at was USD 9.51984. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in PRTA has increased by USD 18,758 compared to the previous valuation of Prothena Corporation plc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 78.9 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 78.9. The average price that PTCT shares were previous bought at was USD 61.5052. The current market price is 28.3% higher than average price they were purchased at. The value of the holding in PTCT has increased by USD 18,126 compared to the previous valuation of PTC Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| PTGX - Protagonist Therapeutics Inc | HOLD | 0 @ USD 87.41 | USD 0 | The current share valuation price of PTGX based on adjusted close was USD 87.41. The average price that PTGX shares were previous bought at was USD 65.1832. The current market price is 34.1% higher than average price they were purchased at. The value of the holding in PTGX has increased by USD 58,163 compared to the previous valuation of Protagonist Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| QURE - Uniqure NV | HOLD | 0 @ USD 24.98 | USD 0 | The current share valuation price of QURE based on adjusted close was USD 24.98. The average price that QURE shares were previous bought at was USD 23.6727. The current market price is 5.5% higher than average price they were purchased at. The value of the holding in QURE has increased by USD 42,187 compared to the previous valuation of Uniqure NV however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| RAPT - RAPT Therapeutics Inc | HOLD | 0 @ USD 36.47 | USD 0 | |
| RARE - Ultragenyx | HOLD | 0 @ USD 34.75 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 34.75. The average price that RARE shares were previous bought at was USD 35.9847. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in RARE has increased by USD 82,500 compared to the previous valuation of Ultragenyx however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| RARE - WISETFWTMRARETFP | HOLD | 0 @ USD 34.75 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 34.75. The average price that RARE shares were previous bought at was USD 35.9847. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in RARE has increased by USD 82,500 compared to the previous valuation of WISETFWTMRARETFP however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| RCKT - Rocket Pharmaceuticals Inc | HOLD | 0 @ USD 3.53 | USD 0 | The current share valuation price of RCKT based on adjusted close was USD 3.53. The average price that RCKT shares were previous bought at was USD 4.68034. The current market price is -24.6% lower than average price they were purchased at. The value of the holding in RCKT has increased by USD 23,337 compared to the previous valuation of Rocket Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 779.36 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 779.36. The average price that REGN shares were previous bought at was USD 651.544. The current market price is 19.6% higher than average price they were purchased at. The value of the holding in REGN has increased by USD 805,467 compared to the previous valuation of Regeneron Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| REPL - Replimune Group Inc | HOLD | 0 @ USD 9.93001 | USD 0 | The current share valuation price of REPL based on adjusted close was USD 9.93001. The average price that REPL shares were previous bought at was USD 9.21424. The current market price is 7.8% higher than average price they were purchased at. The value of the holding in REPL has increased by USD 2,669 compared to the previous valuation of Replimune Group Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 14.97 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 14.97. The average price that RGNX shares were previous bought at was USD 10.0677. The current market price is 48.7% higher than average price they were purchased at. The value of the holding in RGNX has increased by USD 13,160 compared to the previous valuation of Regenxbio Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 8.61 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 8.61. The average price that RLAY shares were previous bought at was USD 4.92682. The current market price is 74.8% higher than average price they were purchased at. The value of the holding in RLAY has increased by USD 24,899 compared to the previous valuation of Relay Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| RNA - Avidity Biosciences Inc | HOLD | 0 @ USD 72.2 | USD 0 | The current share valuation price of RNA based on adjusted close was USD 72.2. The average price that RNA shares were previous bought at was USD 50.9908. The current market price is 41.6% higher than average price they were purchased at. The value of the holding in RNA has fallen by USD 14,431 compared to the previous valuation of Avidity Biosciences Inc |
| ROIV - Roivant Sciences Ltd | HOLD | 0 @ USD 22.68 | USD 0 | The current share valuation price of ROIV based on adjusted close was USD 22.68. The average price that ROIV shares were previous bought at was USD 15.3244. The current market price is 48.0% higher than average price they were purchased at. The value of the holding in ROIV has increased by USD 128,461 compared to the previous valuation of Roivant Sciences Ltd however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 38.86 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 38.86. The average price that RPRX shares were previous bought at was USD 36.7111. The current market price is 5.9% higher than average price they were purchased at. The value of the holding in RPRX has increased by USD 75,992 compared to the previous valuation of Royalty Pharma Plc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| RVMD - Revolution Medicines Inc | HOLD | 0 @ USD 80.58 | USD 0 | The current share valuation price of RVMD based on adjusted close was USD 80.58. The average price that RVMD shares were previous bought at was USD 50.4416. The current market price is 59.7% higher than average price they were purchased at. The value of the holding in RVMD has increased by USD 238,048 compared to the previous valuation of Revolution Medicines Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.4 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.4. The average price that RXRX shares were previous bought at was USD 5.29733. The current market price is -16.9% lower than average price they were purchased at. The value of the holding in RXRX has increased by USD 49,245 compared to the previous valuation of Recursion Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 112.88 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 112.88. The average price that RYTM shares were previous bought at was USD 83.9526. The current market price is 34.5% higher than average price they were purchased at. The value of the holding in RYTM has increased by USD 33,784 compared to the previous valuation of Rhythm Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| SANA - Sana Biotechnology Inc | HOLD | 0 @ USD 4.57 | USD 0 | The current share valuation price of SANA based on adjusted close was USD 4.57. The average price that SANA shares were previous bought at was USD 3.48775. The current market price is 31.0% higher than average price they were purchased at. The value of the holding in SANA has increased by USD 38,056 compared to the previous valuation of Sana Biotechnology Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| SIGA - SIGA Technologies Inc | HOLD | 0 @ USD 6.25 | USD 0 | The current share valuation price of SIGA based on adjusted close was USD 6.25. The average price that SIGA shares were previous bought at was USD 6.62905. The current market price is -5.7% lower than average price they were purchased at. The value of the holding in SIGA has fallen by USD 1,024 compared to the previous valuation of SIGA Technologies Inc |
| SMMT - Summit Therapeutics PLC | HOLD | 0 @ USD 18.15 | USD 0 | The current share valuation price of SMMT based on adjusted close was USD 18.15. The average price that SMMT shares were previous bought at was USD 20.3075. The current market price is -10.6% lower than average price they were purchased at. The value of the holding in SMMT has increased by USD 168,060 compared to the previous valuation of Summit Therapeutics PLC however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| SNDX - Syndax Pharmaceuticals Inc | HOLD | 0 @ USD 21.48 | USD 0 | The current share valuation price of SNDX based on adjusted close was USD 21.48. The average price that SNDX shares were previous bought at was USD 14.1601. The current market price is 51.7% higher than average price they were purchased at. The value of the holding in SNDX has increased by USD 42,215 compared to the previous valuation of Syndax Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| SNY - Sanofi ADR | HOLD | 0 @ USD 48.03 | USD 0 | The current share valuation price of SNY based on adjusted close was USD 48.03. The average price that SNY shares were previous bought at was USD 49.8849. The current market price is -3.7% lower than average price they were purchased at. The value of the holding in SNY has fallen by USD 27,154 compared to the previous valuation of Sanofi ADR |
| SPRY - Silverback Therapeutics Inc | HOLD | 0 @ USD 11.36 | USD 0 | The current share valuation price of SPRY based on adjusted close was USD 11.36. The average price that SPRY shares were previous bought at was USD 12.3064. The current market price is -7.7% lower than average price they were purchased at. The value of the holding in SPRY has increased by USD 58,831 compared to the previous valuation of Silverback Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 21.23 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 21.23. The average price that SRPT shares were previous bought at was USD 30.2726. The current market price is -29.9% lower than average price they were purchased at. The value of the holding in SRPT has increased by USD 13,833 compared to the previous valuation of Sarepta Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| SRRK - Scholar Rock Holding Corp | HOLD | 0 @ USD 45.2 | USD 0 | The current share valuation price of SRRK based on adjusted close was USD 45.2. The average price that SRRK shares were previous bought at was USD 36.9091. The current market price is 22.5% higher than average price they were purchased at. The value of the holding in SRRK has increased by USD 91,727 compared to the previous valuation of Scholar Rock Holding Corp however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 33.52 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 33.52. The average price that STOK shares were previous bought at was USD 19.8446. The current market price is 68.9% higher than average price they were purchased at. The value of the holding in STOK has increased by USD 60,955 compared to the previous valuation of Stoke Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 51.5 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 51.5. The average price that SUPN shares were previous bought at was USD 39.6336. The current market price is 29.9% higher than average price they were purchased at. The value of the holding in SUPN has increased by USD 785 compared to the previous valuation of Supernus Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| SVRA - Savara Inc | HOLD | 0 @ USD 6.47 | USD 0 | The current share valuation price of SVRA based on adjusted close was USD 6.47. The average price that SVRA shares were previous bought at was USD 4.24735. The current market price is 52.3% higher than average price they were purchased at. The value of the holding in SVRA has increased by USD 58,460 compared to the previous valuation of Savara Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| SYRE - Spyre Therapeutics Inc. | HOLD | 0 @ USD 34.2 | USD 0 | The current share valuation price of SYRE based on adjusted close was USD 34.2. The average price that SYRE shares were previous bought at was USD 24.6779. The current market price is 38.6% higher than average price they were purchased at. The value of the holding in SYRE has increased by USD 42,464 compared to the previous valuation of Spyre Therapeutics Inc. however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| TARS - Tarsus Pharmaceuticals Inc | HOLD | 0 @ USD 81.98 | USD 0 | The current share valuation price of TARS based on adjusted close was USD 81.98. The average price that TARS shares were previous bought at was USD 57.0634. The current market price is 43.7% higher than average price they were purchased at. The value of the holding in TARS has increased by USD 16,842 compared to the previous valuation of Tarsus Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| TBPH - Theravance Biopharma Inc | HOLD | 0 @ USD 18.81 | USD 0 | The current share valuation price of TBPH based on adjusted close was USD 18.81. The average price that TBPH shares were previous bought at was USD 13.6055. The current market price is 38.3% higher than average price they were purchased at. The value of the holding in TBPH has increased by USD 681 compared to the previous valuation of Theravance Biopharma Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| TERN - Tern Plc | HOLD | 0 @ USD 40.64 | USD 0 | The current share valuation price of TERN based on adjusted close was USD 40.64. The average price that TERN shares were previous bought at was USD 11.7882. The current market price is 244.8% higher than average price they were purchased at. The value of the holding in TERN has increased by USD 45,601 compared to the previous valuation of Tern Plc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.04749. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| TNGX - Tango Therapeutics Inc | HOLD | 0 @ USD 8.62 | USD 0 | The current share valuation price of TNGX based on adjusted close was USD 8.62. The average price that TNGX shares were previous bought at was USD 7.61917. The current market price is 13.1% higher than average price they were purchased at. The value of the holding in TNGX has increased by USD 9,213 compared to the previous valuation of Tango Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| TRDA - Entrada Therapeutics Inc | HOLD | 0 @ USD 10.62 | USD 0 | The current share valuation price of TRDA based on adjusted close was USD 10.62. The average price that TRDA shares were previous bought at was USD 8.26934. The current market price is 28.4% higher than average price they were purchased at. The value of the holding in TRDA has fallen by USD 9,275 compared to the previous valuation of Entrada Therapeutics Inc |
| TSHA - Taysha Gene Therapies Inc | HOLD | 0 @ USD 5.86 | USD 0 | The current share valuation price of TSHA based on adjusted close was USD 5.86. The average price that TSHA shares were previous bought at was USD 3.28075. The current market price is 78.6% higher than average price they were purchased at. The value of the holding in TSHA has increased by USD 69,333 compared to the previous valuation of Taysha Gene Therapies Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| TVTX - Travere Therapeutics Inc | HOLD | 0 @ USD 36.5 | USD 0 | The current share valuation price of TVTX based on adjusted close was USD 36.5. The average price that TVTX shares were previous bought at was USD 24.3859. The current market price is 49.7% higher than average price they were purchased at. The value of the holding in TVTX has increased by USD 121,804 compared to the previous valuation of Travere Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 35.06 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 35.06. The average price that TWST shares were previous bought at was USD 34.5907. The current market price is 1.4% higher than average price they were purchased at. The value of the holding in TWST has increased by USD 106,669 compared to the previous valuation of Twist Bioscience Corp however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 16.94 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 16.94. The average price that TXG shares were previous bought at was USD 13.6014. The current market price is 24.5% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 70,915 compared to the previous valuation of 10X Genomics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| TXG - Terex Corporation | HOLD | 0 @ USD 16.94 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 16.94. The average price that TXG shares were previous bought at was USD 13.6014. The current market price is 24.5% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 70,915 compared to the previous valuation of Terex Corporation however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| URGN - UroGen Pharma Ltd | HOLD | 0 @ USD 23.58 | USD 0 | The current share valuation price of URGN based on adjusted close was USD 23.58. The average price that URGN shares were previous bought at was USD 17.004. The current market price is 38.7% higher than average price they were purchased at. The value of the holding in URGN has increased by USD 24,977 compared to the previous valuation of UroGen Pharma Ltd however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 513.79 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 513.79. The average price that UTHR shares were previous bought at was USD 383.252. The current market price is 34.1% higher than average price they were purchased at. The value of the holding in UTHR has fallen by USD 98,380 compared to the previous valuation of United Therapeutics Corporation |
| VCEL - Vericel Corp Ord | HOLD | 0 @ USD 37.37 | USD 0 | The current share valuation price of VCEL based on adjusted close was USD 37.37. The average price that VCEL shares were previous bought at was USD 39.8793. The current market price is -6.3% lower than average price they were purchased at. The value of the holding in VCEL has increased by USD 45,668 compared to the previous valuation of Vericel Corp Ord however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 43.09 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 43.09. The average price that VCYT shares were previous bought at was USD 35.1548. The current market price is 22.6% higher than average price they were purchased at. The value of the holding in VCYT has increased by USD 9,193 compared to the previous valuation of Veracyte Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| VERA - Vera Therapeutics Inc | HOLD | 0 @ USD 53.78 | USD 0 | The current share valuation price of VERA based on adjusted close was USD 53.78. The average price that VERA shares were previous bought at was USD 30.451. The current market price is 76.6% higher than average price they were purchased at. The value of the holding in VERA has increased by USD 111,957 compared to the previous valuation of Vera Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 6.01 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 6.01. The average price that VIR shares were previous bought at was USD 5.93668. The current market price is 1.2% higher than average price they were purchased at. The value of the holding in VIR has increased by USD 23,202 compared to the previous valuation of Vir Biotechnology Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| VIR - Vidrala S.A | HOLD | 0 @ USD 6.01 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 6.01. The average price that VIR shares were previous bought at was USD 5.93668. The current market price is 1.2% higher than average price they were purchased at. The value of the holding in VIR has increased by USD 23,202 compared to the previous valuation of Vidrala S.A however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 7.03001 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 7.03001. The average price that VNDA shares were previous bought at was USD 4.93435. The current market price is 42.5% higher than average price they were purchased at. The value of the holding in VNDA has increased by USD 11,206 compared to the previous valuation of Vanda Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 460.31 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 460.31. The average price that VRTX shares were previous bought at was USD 443.427. The current market price is 3.8% higher than average price they were purchased at. The value of the holding in VRTX has increased by USD 705,153 compared to the previous valuation of Vertex Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| VTRS - Viatris Inc | HOLD | 0 @ USD 12.01 | USD 0 | The current share valuation price of VTRS based on adjusted close was USD 12.01. The average price that VTRS shares were previous bought at was USD 9.93876. The current market price is 20.8% higher than average price they were purchased at. The value of the holding in VTRS has increased by USD 63,033 compared to the previous valuation of Viatris Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| VTYX - Ventyx Biosciences Inc | HOLD | 0 @ USD 9.33999 | USD 0 | |
| VYGR - Voyager Therapeutics Inc | HOLD | 0 @ USD 4.21001 | USD 0 | The current share valuation price of VYGR based on adjusted close was USD 4.21001. The average price that VYGR shares were previous bought at was USD 3.94785. The current market price is 6.6% higher than average price they were purchased at. The value of the holding in VYGR has increased by USD 7,877 compared to the previous valuation of Voyager Therapeutics Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| WVE - Wave Life Sciences Ltd | HOLD | 0 @ USD 17.97 | USD 0 | The current share valuation price of WVE based on adjusted close was USD 17.97. The average price that WVE shares were previous bought at was USD 8.32984. The current market price is 115.7% higher than average price they were purchased at. The value of the holding in WVE has increased by USD 227,592 compared to the previous valuation of Wave Life Sciences Ltd however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| XENE - Xenon Pharmaceuticals Inc | HOLD | 0 @ USD 46.08 | USD 0 | The current share valuation price of XENE based on adjusted close was USD 46.08. The average price that XENE shares were previous bought at was USD 37.74. The current market price is 22.1% higher than average price they were purchased at. The value of the holding in XENE has increased by USD 104,671 compared to the previous valuation of Xenon Pharmaceuticals Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| XERS - Xeris Pharmaceuticals Inc | HOLD | 0 @ USD 7.21 | USD 0 | The current share valuation price of XERS based on adjusted close was USD 7.21. The average price that XERS shares were previous bought at was USD 6.25114. The current market price is 15.3% higher than average price they were purchased at. The value of the holding in XERS has fallen by USD 14,756 compared to the previous valuation of Xeris Pharmaceuticals Inc |
| XNCR - Xencor Inc | HOLD | 0 @ USD 15.97 | USD 0 | The current share valuation price of XNCR based on adjusted close was USD 15.97. The average price that XNCR shares were previous bought at was USD 12.6245. The current market price is 26.5% higher than average price they were purchased at. The value of the holding in XNCR has increased by USD 20,517 compared to the previous valuation of Xencor Inc however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| ZLAB - Zai Lab Ltd | HOLD | 0 @ USD 17.71 | USD 0 | The current share valuation price of ZLAB based on adjusted close was USD 17.71. The average price that ZLAB shares were previous bought at was USD 30.9501. The current market price is -42.8% lower than average price they were purchased at. The value of the holding in ZLAB has fallen by USD 8,839 compared to the previous valuation of Zai Lab Ltd |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 27.62 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 27.62. The average price that ZYME shares were previous bought at was USD 17.4588. The current market price is 58.2% higher than average price they were purchased at. The value of the holding in ZYME has increased by USD 19,966 compared to the previous valuation of Zymeworks Inc. Common Stock however if the holding was sold on 2025-12-22 this would crystalise an overall loss. |
| OKUR - OKUR | SELL | -290 @ USD 2.95897 | USD -858 | The ETF sold 290 shares of OKUR on 2025-12-22. The shares were previously bought for an average price of USD 5.61305. The OKUR shares were sold for -47.3% lower than average price of previous purchases. This resulted in an overall loss of USD 770 The average price that the ETF previously sold OKUR share for is USD 3.23138 which is higher than the selling price of USD 2.95897 on 2025-12-22. |
| FATE - Fate Therapeutics Inc | SELL | -8,316 @ USD 1.04996 | USD -8,731 | The ETF sold 8316 shares of FATE on 2025-12-22. The shares were previously bought for an average price of USD 1.14824. The Fate Therapeutics Inc shares were sold for -8.6% lower than average price of previous purchases. This resulted in an overall loss of USD 817 The average price that the ETF previously sold FATE share for is USD 1.04591 so the ETF has sold 8316 shares on 2025-12-22 at a higher price than the previous selling average. |
| ERAS - Erasca Inc | SELL | -5,068 @ USD 3.65 | USD -18,498 | The ETF sold 5068 shares of ERAS on 2025-12-22. The shares were previously bought for an average price of USD 2.03843. The Erasca Inc shares were sold for 79.1% higher than average price of previous purchases. This sale made a profit of USD 8,167 The average price that the ETF previously sold ERAS share for is USD 2.48071 so the ETF has sold 5068 shares on 2025-12-22 at a higher price than the previous selling average. |
| CYTK - Cytokinetics Inc | SELL | -4,483 @ USD 65.6 | USD -294,085 | The ETF sold 4483 shares of CYTK on 2025-12-22. The shares were previously bought for an average price of USD 49.2666. The Cytokinetics Inc shares were sold for 33.2% higher than average price of previous purchases. This sale made a profit of USD 73,223 The average price that the ETF previously sold CYTK share for is USD 46.5317 so the ETF has sold 4483 shares on 2025-12-22 at a higher price than the previous selling average. |